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Thyroiddiseasesaremoreprevalentinwomen,particularlybetweenpubertyandmenopause.Itiswellknownthatestrogen(E)has
indirect eﬀects on the thyroid economy. Direct eﬀects of this steroid hormone on thyroid cells have been described more recently;
so, the aim of the present paper was to review the evidences of these eﬀects on thyroid function and growth regulation, and its
mechanisms. The expression and ratios of the two E receptors, α and β, that mediate the genomic eﬀects of E on normal and
abnormal thyroid tissue were also reviewed, as well as nongenomic, distinct molecular pathways. Several evidences support the
hypothesis that E has a direct role in thyroid follicular cells; understanding its inﬂuence on the growth and function of the thyroid
in normal and abnormal conditions can potentially provide new targets for the treatment of thyroid diseases.
1.Introduction
Thyroid diseases are more prevalent in women particularly
between puberty and menopause [1], and women are more
susceptible to the goitrogenic eﬀect of iodine deﬁciency [2].
Carcinomas of the thyroid are three-times more frequent
in women than in men, and the peak rates occur earlier
in women [3]. These epidemiological data suggest a role of
estrogen in the pathogenesis of thyroid diseases.
Estrogen has a well-known indirect eﬀect on thyroid
economy, increasing the thyroxine binding globulin [4], and
the need for thyroid hormone in hypothyroid women [5].
Directeﬀectsofestrogenonthyroidcellshavebeendescribed
more recently [6], so the aim of the present paper was to
review the evidences of these eﬀects on thyroid function and
growth regulation, and its mechanisms.
2. Estrogen andIts Receptors
17-β-estradiol (E2) is a lipophilic hormone with low-
molecular weight that occurs naturally. Cellular signaling
of estrogen is mediated classically upon the binding on
two soluble intracellular nuclear receptors, estrogen receptor
(ER) alpha, and ER beta [7]. The isoform β is smaller
than the isoform α, and the DNA-binding domains of both
subtypes are highly conserved. After binding of E2, ER
forms a stable dimer that interacts with speciﬁc sequences
called estrogen response elements (EREs) to initiate the
transcription of target genes. Ligand-bound ERs can also
interact with other transcription factors complexes and
inﬂuence transcription of genes that do not harbor EREs.
Third and fourth mechanisms of ERs regulatory actions
are, respectively, non-genomic and the ligand independent
pathway.Avarietyofrapidsignalingeventssuchasactivation
ofkinasesandphosphatasesandincreasesinionﬂuxesacross
membranes has been described. These and other aspects of
signaling and targets of ERs have been reviewed recently [7].
Recently, a transmembrane intracellular nonclassical ER
mediating rapid cell signaling was described, a G protein-
coupled receptor (GPCR), named GPR30 [8].
2.1. Expression of ERs in Human Thyroid Tissue. Classically,
the presence of ER is fundamental for a direct action of
estrogen in a given cell. ER has been described in both
neoplastic and nonneoplastic human thyroid tissues, but
the results are discordant. Immunohistochemical assays,2 Journal of Thyroid Research
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Table 2: Estrogen receptors (ER) α and β in human normal thyroid, and benign and malignant thyroid diseases, by immunohistochemistry
(IHC).
Study Isoform All benign All carcinoma Benign lesions Carcinoma
Adenoma Goiter Papillary Follicular Medullary Anaplastic
Vaiman et al. [31]; 2010 ERα 0/34 0/150 0/90 0/6 0/4 0/5
ERβ 30/34 126/150 60/90 4/6 3/4 3/5
Winters et al. [32]; 2010 ERα 1/1
Vannucchi et al. [33]; 2010 ERα 12/38
Cho et al. [34]; 2007 ERα 10/11
ERβ 8/11
Bl´ e c h e te ta l .[ 35]; 2007 ERα 0/28
ERβ 26/28
Ceresini et al. [36]; 2006 ERα 0/17 0/17
ERβ 17/17 14/17
Data are shown as number of ER-positive samples/total number of samples.
with monoclonal antibodies, are the most commonly used
methods for establishing receptor status. As may be seen in
Table 1,somestudieshavefoundER-positivityinnormaland
abnormal thyroid tissue while others have not detected ER
protein in any tissue studied. This discrepancy could be due
to methodological issues; the development of monoclonal
antibodies against ER with high sensitivity and speciﬁcity,
and others factors such as tissue ﬁxation, tissue processing,
interpretation of immunohistochemistry, and cutoﬀs for
positive results, could have contributed to the sensitivity of
the techniques employed [9].
2.2.Expressionof ERαandERβ inHumanThyroidTissue. ER
expression in human thyroid was ﬁrst reported in 1981 [37].
ERα was ﬁrst described in 1973 [38], and ERβ was identiﬁed
in 1996 [39], so only from this moment on it was possible to
evaluate the relationship between isoforms of ERs in thyroid
tissue. An important role of diﬀerent patterns of distribution
and expression of subtypes ERs in thyroid carcinoma has
been proposed: estrogen binding to ERα would promote
cell proliferation and growth, and, in contrast, ERβ would
promote apoptotic actions and other suppressive functions
in thyroid tumors, as reviewed by Chen et al. [40]. Then,
ERα:ERβ ratio could have a role in the pathophysiology
of thyroid cancer [40], similar to that postulated for breast
cancer [41].
In diﬀerentiated thyroid follicular tumors, the expression
of ERα has been associated with well-diﬀerentiated tumors
and reduced incidence of disease recurrence [54]. ERα
protein [55]a n dE R α mRNA [19, 56] are expressed in
normal and neoplastic follicular cells of the thyroid. Also,
the expression of ERα and ERβ was detected in human
medullary thyroid cancer [34] with an increased ratio of
ERα/ERβ, suggesting a possible role in tumor growth and
progression.AfewstudiesevaluatedERαandERβexpression
in normal and abnormal thyroid tissue, as shown in Table 2.
The eﬀects of the agonists of ERα and ERβ,r e s p e c t i v e l y ,
propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN),
in the proliferation of thyroid cancer cell lines has been
studied: PPT had a stimulatory eﬀect, while inhibition of
proliferation and DNA fragmentation were observed after
DPN [45]. In the same study, small interference ribonucleic
acid(siRNA)blockingERαorERβdemonstratedthatknock-
down of the ERα attenuated E2-mediated B-cell lymphoma
2 (Bcl-2) expression, an important antiapoptotic protein,
while knockdown of the ERβ enhanced E2-induced Bcl-2
expression [45].
2.3. Expression of GPR30 in Thyroid Cells Lines. Growing
evidence suggests that estrogens are also able to exert non-
genomic events mediated by GPR30 [8]. Vivacqua and
colleagues analyzed the eﬀects of E2 and the phytoestrogen
genistein in human follicular thyroid carcinoma cell lines,
WRO and FRO, and ARO, a human anaplastic thyroid
carcinoma cell line [46]. Both hormones stimulated in
vitro proliferation of these cell lines through the GPR30
and mitogen-activated protein kinase signaling cascade [46].
In other human benign and malignant thyroid tissue, the
expression of GPR30 has not been studied.
3. Response to E2StimulationIn Vitro
3.1. Proliferation. Several studies described proliferation of
thyroid cells induced by E2, as shown in Table 3.S o m eo f
the most commonly used assays are incorporation of bro-
modeoxyuridine (BrdU) [6], 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) [45, 47, 50, 57],
[(3)H]-thymidine incorporation [48, 52, 53], and trypan
blue solution [43]. Cotreatment with ICI182780, fulvestrant,
anantagonistofE2byinhibitionanddegradationofER[58],
signiﬁcantly attenuated these proliferative eﬀects.
Based in these studies, E2 increases proliferation of
thyroid cells.
3.2. ER-Dependent Eﬀects on Thyroid Diﬀerentiation Proteins.
Few studies evaluated E2 eﬀect on gene transcription of4 Journal of Thyroid Research
Table 3: E2 eﬀects on thyroid protein expression, function, and proliferation in vitro.
Study Thyroid cells Presence of ERα/ERβ Erα
expression
Erβ
expression Proliferation Nis
expression
Iodide
uptake
TG
mRNA
Kumar et al. [42]; 2010 NPA87 ERα+/ERβ+ ↑
KAT5 ERα+/ERβ+ ↑
WRO ERα+/ERβ+ ↑
Rajoria et al. [43]; 2010 BCPAP ERα+/ERβ+ ↑
Nthy-3-1 ERα+/ERβ+ ↑
Zeng et al. [44]; 2008 KAT5 ERα+/ERβ+ ↑ 0 ↑
FRO ERα+/ERβ+0↑↓
Zeng et al. [45]; 2007 KAT5 ERα+/ERβ+ ↑ 0 ↑
FRO ERα+/ERβ+ ↑↑ ↑
ARO ERα+/Erβ+ ↑ 0 ↑
Vivacqua et al. [46]; 2006 WRO ERα+/ERβ−↑
FRO ERα+/ERβ−↑
ARO ERα−/ERβ−↑
Lee et al. [47]; 2005 KAT5 ↑
Banu et al. [48]; 2001 NPA87 ER+ ↑ ↑
WRO ER+ ↓
Manole et al. [6]; 2001 HTC-TSHr ERα+/ERβ+ ↑↑ ↑
Goiter ERα+/ERβ+ ↑↑ ↑
XTC 133 ↑
Furlanetto et al. [49]; 2001 FRTL-5 ↑↓
Furlanetto et al. [50]; 1999 FRTL-5 ERα+ ↑↓
Nagy et al. [51]; 1999∗ Mng ↑
Ca ↑
Ade ↓
D e lS e n n oe ta l .[ 52]; 1989∗∗ N ↑↑
Ade ↑↑
Ca 0 0
Yang et al. [53]; 1988 TT ↑
Estrogen receptor (ER) +: presence of expression, –: absence of expression; NPA87, KAT5, and BCPAP: human papillary thyroid carcinoma cell lines; WRO
and FRO: human follicular thyroid carcinoma cell lines; Nthy-3-1: human normal transformed thyroid cell line; ARO: human anaplastic thyroid carcinoma
cell line; HTC-TSHr: human thyroid carcinoma cell line lacking endogenous TSH receptor; XTC-133: thyroid cancer cell line of Hurthle cell origin; FRTL-5:
Fischer rat thyroid cell line. Mng: multinodular goiter; Ca: carcinoma; Ade: adenoma; N: normal thyroid; TT: human medullary thyroid carcinoma cell line;
↑: increase, ↓: decrease, and 0: no eﬀect, after E2 exposure. ∗: thyroid tissue obtained in surgical resection, under organotypic culture conditions for 48 hours;
∗∗: suspension cultures of thyroid follicles.
diﬀerentiation proteins in thyroid cells. In Fischer rat
derived thyroid cell line, FRTL-5, E2 treatment decreased
the sodium-iodide symporter (NIS) gene expression [50],
and the iodide uptake [49]. E2 increased the thyroglobulin
gene expression in suspension cultures of human thyroid
follicles of adenoma and carcinoma [52]. These data are
shown in Table 3. The opposite eﬀects of E2 on the NIS
gene expression and iodide uptake, in FRTL-5 cells, and
the thyroglobulin gene expression, in suspension culture of
thyroid cells, could be due to the diﬀerent systems studied;
it cannot be excluded that estradiol aﬀects these genes
by diﬀerent intracellular pathways. These results, together
with the increase in cell growth caused by estrogen, could
implicate this hormone in the pathogenesis of goiter and
thyroid carcinoma; nevertheless, as just one study evaluated
the eﬀect of estrogen on thyroid diﬀerentiated proteins in
human thyroid tissue, more studies should be done to better
understand the role of estrogen in thyroid diﬀerentiated
protein expression.
3.3. Non-Genomic Eﬀects of E2. Some of the actions of
E2 in the proliferation of thyroid cells are mediated by
the activation of signal transducing pathways, as shown inJournal of Thyroid Research 5
Table 4: Non-genomic estrogen eﬀects on thyroid cells.
Study Cells GPR30 MAPK PI3k Cyclin D1 c-fos BcL-2 Bax
Kumar et al. [42]; 2010 NPA87 −↑ ↑
KAT5 −↑ ↑ ↑
WRO + ↑↑ ↑
Zeng et al. [45]; 2007 KAT5 ↑↓
FRO ↑↓
WRO ↑↓
Vivacqua et al. [46]; 2006 WRO + ↑↑ ↑
FRO + ↑↑ ↑
ARO + ↑↑ ↑
Manole et al. [6]; 2001 HTC-TSHr ↑↑
Goiter ↑↑
XTC 133 ↑↑
NPA87 and KAT5: human papillary thyroid carcinoma cell lines; WRO and FRO: human follicular thyroid carcinoma cell lines; HTC-TSHr: human thyroid
carcinoma cell line lacking endogenous TSH receptor; XTC-133: thyroid cancer cell line of Hurthle cell origin; Goiter: primary culture of human thyroid cells
isolated from goiter nodules. (+): presence of expression; (−) absence of expression; (↑): increase, (↓): decrease, and (0): no eﬀects, after E2 exposure.
Table 4. E2 can induce activation of phosphatidylinositol
3-kinase (PI3K) [42] and phosphorylation of extracellular
signal-regulated kinase 1/2 (ERK1/2) in follicular thyroid
carcinoma cells, mainly due to interaction via membrane-
associated ER [42, 45, 46]. PI3K and Erk1/2 signaling may
play a critical role in preventing apoptosis and inducing
cell cycle progression by induction of key genes expression
[59].
Expression of early response genes and regulatory genes
of the cell cycle are necessary for proliferation of cells.
As E2 has been demonstrated to stimulate the growth of
thyroid cells, it is important to study the expression of
key cell-cycle genes such as cyclin D1 after stimulation
with E2. Cyclin D1 regulates the cell progression cycle
facilitating G1 to S phase transition and also has an estrogen-
responsive regulatory region [60], that is likely diﬀerent
from the canonical EREs. Overexpression of cyclin D1 in
thyroid malignancies has been reported [61–65], moreover,
itsexpressionhasbeenassociatedwithanaggressivebehavior
in papillary thyroid microcarcinomas, because over 90%
of the metastasizing microcarcinomas expressed cyclin D1
[66].
E2 signiﬁcantly increased the expression of cyclin D1 in
a human thyroid carcinoma cell line lacking endogenous
TSH receptor (HTC-TSHr cells), and in a thyroid cancer cell
line of Hurthle cell origin (XTC-133), which was abolished
by PD.098059 that blocked G0/G1 to S phases [6]. E2
u p r e g u l a t e dc y c l i n sAa n dD 1 ,a sw e l la st h ep r o t o - o n c o g e n e
c-fos,i nW R O ,F R O ,a n dA R Oc e l l s[ 46]. Cyclin D1 was also
shown to be upregulated by E2 in KAT5, a papillary thyroid
cancer cell line, and WRO cells [42].
Together, these results are very compelling, pointing
to an ability of E2 to regulate genes mediating cell cycle
progression in thyroid cells, and potentially contributing
to the pathogenesis of thyroid cancer or thyroid hyperpla-
sia.
4. Conclusions
There are evidences that estrogen may have direct actions in
human thyroid cells by ER-dependent mechanisms or not,
modulating proliferation, and function. Diﬀerent patterns of
distribution,expression,andratiosofERαandERβmayhave
a role in thyroid cancer cells proliferation, as well as in the
outcome of thyroid cancer. Studying estrogen eﬀects on thy-
roid cells is a potential tool to better understand the patho-
genesis of thyroid diseases, and to develop targets to its treat-
ment. Further studies on the inﬂuence of E2 on the growth
andfunctionofthethyroidareneeded,preferablyinprimary
culture of normal and abnormal human thyroid cells.
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